Assertion Supported AI assessment confidence: 95% certainty 4/5 debate potential 2/5

Ganguli: FDA-approved drugs target only 800 of roughly 20,000 human genes

Surya Ganguli · AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu · Oct 3, 2024 · at 11:01

Surya Ganguli, venture partner at a16z Bio + Health, explains the vast untapped genomic space remaining for novel AI-designed therapies.

0:00 / 0:07exact quote · 7.6s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“FDA approved drugs they target only 800 of the 20,000 known genes that we have, 20 to 25,000 known genes that we have.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Surya Ganguli states that existing FDA-approved drugs target only 800 out of the 20,000 to 25,000 known human genes.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

Surya Ganguli's statement is accurate based on consensus data from drug target databases and scientific literature. The Human Protein Atlas / DrugBank reports that FDA-approved drugs target 854 separate human proteins. Other major mapping studies and databases (such as Santos et al., the NIH Illuminating the Druggable Genome program, and ChEMBL) place the number of human gene products targeted by FDA-approved drugs between 600 and 850 depending on whether secondary off-target interactions are included. Thus, 'approximately 800' is a precise characterization. Additionally, standard genomic literature confirms the human genome contains approximately 20,000 to 25,000 protein-coding genes.

Human Protein Atlas/DrugBank data reports 854 separate human proteins targeted by current FDA-approved drugs.
Major scientific benchmarks (e.g., Santos et al. 2017, NIH IDG, ChEMBL) place human protein targets of approved drugs between 600 and 850.
Human genome consensus estimates confirm 20,000 to 25,000 protein-coding genes.

Checked against

[1] a16z.com [2] a16z.com [3] sanogenetics.com [4] nih.gov [5] sussex.ac.uk [6] drugdiscoverytrends.com [7] nih.gov [8] proteinatlas.org

"A comprehensive map of molecular drug targets" Santos 2017 667 human protein targets "druggable genome" number of human gene targets FDA approved drugs Surya Ganguli 800 20000 25000 human genes FDA approved drugs a16z podcast how many human genes are targeted by FDA approved drugs number of human gene products targeted by FDA approved drugs DrugBank ChEMBL

assessed as of 2026-07-28

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

FDA approved drugs human genes Surya Ganguli

⚑ Spot an error? Report it

More from Surya Ganguli

Insight

Ganguli: Specialized Models Beat Fine-Tuned Foundation Models for Specific Tasks

“You really, I think you're best off with a specialized model trained on the data that's very relevant to the thing, the task you want to solve. Your second best bet is to start with a foundation model that understands the broad space and fine tune it. Again, o…”

Surya Ganguli Oct 3, 2024 ▶ 16:11 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Insight

Ganguli: Evolutionary robustness proves low-dimensional structure controls biological function

“Biological systems have survived for almost four billion years of evolution. They've tolerated all sorts of insults, competition, and so forth, so they're extremely robust. Because they're robust, their function can't depend on all of the details. That means t…”

Surya Ganguli Oct 3, 2024 ▶ 21:53 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Insight

Ganguli: ESMFold proves language models can learn protein structure from sequences

“I was actually really impressed by ESM fold, this average scale modeling where you could kind of do the same thing that you do for language, but do it for sequences. And then you learn representations that know about the structure of proteins.”

Surya Ganguli Oct 3, 2024 ▶ 0:47 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Assertion Supported

Ganguli: ESM-3 model trained on 2.8 billion amino acid sequences

“ESM-III with evolutionary scale modeling did the same language modeling, but now on amino acid sequences of about 2.8 billion sequences, right?”

Surya Ganguli Oct 3, 2024 ▶ 5:02 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Assertion Supported

Ganguli: Bringing a drug to market costs $2.5B and takes 10–15 years

“The cost of drug design, I mean, I know in the industry this is well known, but it's worth, worth emphasizing, it's 2.5 billion dollars per drug in 10 to 15 years, right?”

Surya Ganguli Oct 3, 2024 ▶ 10:33 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Assertion Supported

Ganguli: 90% of drug candidates fail to achieve FDA approval

“90% of drug candidates don't get FDA approval.”

Surya Ganguli Oct 3, 2024 ▶ 10:44 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Ganguli: FDA-approved drugs target only 800 of roughly 20,000 human genes

More from Surya Ganguli

Turn any episode into a week of clips.